Needham & Co downgrades Poniard Pharmaceuticals (Nasdaq: PARD) from Buy to Hold.

Needham analyst says, "This morning, the Poniard management ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE